Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD-optimised meropenem or piperacillin/tazobactam dosing in ICU patients with sepsis or septic shock
ACTRN12620000665932Phase 3Completed
- Sponsor
- The University of Queensland
- Start
- Mar 2021
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meropenem and piperacillin + tazobactam in sepsis, septic shock and Infection (2 arms), sponsored by The University of Queensland. Primary endpoint: Safety and tolerability of PK/PD-based dosing. Started Mar 2021; status: completed.
02
Drugs
meropenempiperacillin + tazobactam
03
Conditions
sepsisseptic shockInfection
Beyond the preview
Go deeper on ACTRN12620000665932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000665932.